Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020

Publication date: January 2012

Keywords : diabete, cardiovascular disease, Gestational diabetes, retinopathy, obesity

Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Lyxumia sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The re...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Lyxumia sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Lyxumia
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Lyxumia including efficacy, safety, pricing and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Lyxumia in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Pathology Industry in the United Kingdom

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11
3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15
4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18
6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24
7 Lyxumia 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.4 Factors Affecting Sales of Lyxumia 25
7.4.1 Compliance of Lyxumia 25
7.4.2 Potential Benefits 26
7.4.3 Good Safety Profile 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 27
7.6.1 Target Patient Pool for Lyxumia 27
7.6.2 Dosing 27
7.6.3 Market Penetration 27
7.6.4 Annual Cost of Therapy 28
7.6.5 Sales Projections of Lyxumia 29
8 Diabetes Market: Appendix 38
8.1 Market Definitions 38
8.2 List of Abberiviations 38
8.3 Research Methodology 38
8.3.1 Coverage 38
8.3.2 Secondary Research 39
8.3.3 Forecasting 39
8.3.4 Number of patients approved to take the drug 39
8.3.5 Net Penetration of Drug 40
8.3.6 Net Annual Dosing 40
8.3.7 Annual Cost of Therapy 40
8.4 Drug Sales Estimates Model 40
8.5 Contact Us 40
8.6 Disclaimer 40
8.7 Sources 41

1.1 List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of Lyxumia 26
Table 10: Annual Cost of Therapy of Lyxumia, 2013 28
Table 11: Lyxumia, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020 29
Table 12: Lyxumia, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020 30
Table 13: Lyxumia, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020 31
Table 14: Lyxumia, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020 32
Table 15: Lyxumia, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020 33
Table 16: Lyxumia, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020 34
Table 17: Lyxumia, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020 35
Table 18: Lyxumia, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2013–2020 36

List of Figures

Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
Figure 12: Lyxumia, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020 29
Figure 13: Lyxumia, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020 30
Figure 14: Lyxumia, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020 31
Figure 15: Lyxumia, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020 32
Figure 16: Lyxumia, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020 33
Figure 17: Lyxumia, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020 34
Figure 18: Lyxumia, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020 35
Figure 19: Lyxumia, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2013–2020 36
Figure 20: Lyxumia, Type 2 Diabetes, Sales Distribution by Country (%), 2020 37
Figure 21: Patients Approved for the Drug 39

Endocrine, Nutritional And Metabolic Diseases in United Kingdom